What is an Exploitant?
Under French law, the Exploitant is the entity legally responsible for placing a medicinal product on the French market. That responsibility covers pharmacovigilance, product quality, advertising compliance, and distribution obligations — it is a compliance role, not just an administrative one.
Legal framework and requirements
The role is defined under the French Public Health Code (Code de la Santé Publique) and enforced by the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé). To act as an Exploitant, an entity must:
- Hold an authorisation from the ANSM
- Have an established presence in France
- Maintain qualified staff, including a pharmacien responsable
- Ensure product quality, batch release, and regulatory compliance
- Manage pharmacovigilance and advertising controls
Exploitant vs. MA Holder vs. Distributor
| Role | Primary responsibility | Location | Authority |
|---|---|---|---|
| Exploitant | Placing the product on the French market & ongoing compliance | Must be based in France | ANSM-authorised |
| MA Holder | Owns the marketing authorisation | Anywhere in the EU/EEA | EMA / ANSM-authorised |
| Distributor | Physical distribution of medicines | Flexible | Works under the MA Holder or Exploitant |
Responsibilities of an Exploitant
An Exploitant's obligations span three areas:
- Regulatory & compliance: maintaining ANSM and EU compliance, running pharmacovigilance systems, and approving promotional activity
- Quality & supply: overseeing batch release in France and staying recall-ready
- Commercial accountability: keeping product information accurate for healthcare professionals and patients
When do you need an Exploitant?
You need an Exploitant if any of the following apply:
- You are a non-French pharma company marketing a product in France
- You are launching a product without an ANSM-approved entity already in France
- You want to outsource pharmacovigilance, batch release, or regulatory tasks rather than build that capacity in-house
How to choose the right Exploitant
Weigh candidates against:
- Experience with your specific therapeutic area
- Pharmacovigilance capability and track record
- Compliance history with the ANSM
- Speed of onboarding and responsiveness
- Existing commercial and distribution partnerships
Working with an Exploitant: best practices
- Sign a clear contract that spells out roles and responsibilities
- Keep communication open for regulatory updates as they happen
- Schedule regular performance and compliance reviews rather than treating onboarding as a one-off event
Elliogen's role
Elliogen is not an Exploitant — we're an independent advisor. We help companies identify and compare suitable Exploitants, negotiate agreements that protect their commercial interests, set up the surrounding compliance framework, and streamline the overall market entry.
One US biotech entered France without any local infrastructure. We evaluated three Exploitant candidates and had their compliance setup complete within four months.
Frequently asked questions
Can a foreign company be an Exploitant in France?
Only if it has a physical presence in France and holds ANSM authorisation. Most international pharma and biotech companies instead appoint a locally established Exploitant rather than building that presence themselves.
How long does ANSM Exploitant authorisation take?
Typically 3-6 months, depending on dossier quality and whether an inspection is required. Starting the process early is one of the biggest levers you have over your launch timeline.
Can the Marketing Authorisation Holder also be the Exploitant?
Yes, if the MA Holder meets all the legal requirements — an established presence in France, a qualified pharmacien responsable, and the operational capacity to manage pharmacovigilance, quality, and advertising compliance directly.